Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
Jennifer Bisset was a senior editor for CNET. She covered film and TV news and reviews. The movie that inspired her to want a career in film is Lost in Translation. She won Best New Journalist in 2019 ...
Sorry to burst your bubble right off the bat, but the show hasn’t even been renewed yet. While Welcome to Derry had a strong start, that number quickly fell off in subsequent episodes. That said, it’s ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...
Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...
The last time I wrote about Replimune Group, Inc. (REPL) it was in a Seeking Alpha article entitled "Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch." With respect to this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results